Aktuellt
SENASTE
Redeye leaves a comment following Alzinova’s announcement of a completed primary analysis of the phase Ib study with its vaccine candidate ALZ-101. We are encouraged to learn that the analysis confirms the positive topline results, suggesting that ALZ-101 is well-tolerated and safe, and elicits a high immune response in patients.
LÄS MER
